Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Wednesday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.3885 per share and revenue of $18.79 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Friday, February 13th. The company reported ($0.38) earnings per share for the quarter.

Citius Pharmaceuticals Stock Down 3.3%

Citius Pharmaceuticals stock opened at $0.69 on Wednesday. The stock has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $0.97. The stock has a market capitalization of $15.38 million, a price-to-earnings ratio of -0.28 and a beta of 1.05. Citius Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $2.48.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CTXR shares. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. D. Boral Capital reiterated a “buy” rating and set a $6.00 target price on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Hedge Funds Weigh In On Citius Pharmaceuticals

Large investors have recently made changes to their positions in the company. Heights Capital Management Inc. bought a new position in Citius Pharmaceuticals in the fourth quarter valued at about $622,000. XTX Topco Ltd raised its holdings in Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after purchasing an additional 91,196 shares during the last quarter. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals during the 4th quarter valued at about $46,000. Finally, NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals during the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.